Efficacy and safety of ME3183 , an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis
Journal of the European Academy of Dermatology and Venereology · 2025
DOI: 10.1111/jdv.20863 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von Kim A Papp und 5 weiteren Autor:innen. Beteiligte Einrichtung: Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada. Hauptthemen laut MEDLINE: Psoriasis, Phosphodiesterase 4 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Meiji Pharma USA.
Abstract (Originalsprache)
Background
There is an unmet need for oral psoriasis medications with improved efficacy and safety.
Objective
We evaluated the efficacy and safety of oral ME3183, a novel phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis.
Methods
This was a randomized, double‐blind, placebo‐controlled study with a 16‐week double‐blind treatment period. Patients were randomly assigned (1:1:1:1:1) to oral ME3183 5 mg twice daily (BID), 10 mg once daily (QD), 7.5 mg BID, 15 mg QD or placebo.
Results
In total, 132 patients were randomly assigned to ME3183 5 mg BID (26 patients), 10 mg QD (26 patients), 7.5 mg BID (26 patients), 15 mg QD (27 patients) and placebo (27 patients). The proportions of patients achieving ≥75% reduction in baseline Psoriasis Area and Severity Index scores at Week 16 (primary endpoint) were 58.3%, 32.0%, 61.5% and 52.0% in each ME3183 group, respectively, versus 14.8% in the placebo group (all p < 0.01 vs. placebo, except for the 10 mg QD group). The most common adverse events across the ME3183 groups were diarrhoea (16.0%–38.5%), nausea (7.7%–30.8%) and headache (7.7%–42.3%).
Conclusions
ME3183 should be further investigated as a safe and effective treatment alternative for moderate to severe plaque psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada.
- Division of Dermatology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Division of Dermatology, University of California, Los Angeles, Los Angeles, California, USA.
- Research & Development, Meiji Pharma USA Inc., Teaneck, New Jersey, USA.
ORCID-Profile: Kim A Papp, Kazunari Otake
Förderung
- Meiji Pharma USA
Zitieren
APA
Papp, K. A., Armstrong, A. W., Koresawa, T., Otake, K., Hirata, M., & Kano, A. (2025). Efficacy and safety of ME3183 , an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20863
Vancouver
Papp KA, Armstrong AW, Koresawa T, Otake K, Hirata M, Kano A. Efficacy and safety of ME3183 , an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20863
BibTeX
@article{Papp2025,
author = {Papp, Kim A and Armstrong, April W and Koresawa, Tomokazu and Otake, Kazunari and Hirata, Masayuki and Kano, Akiko},
title = {Efficacy and safety of ME3183 , an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
doi = {10.1111/jdv.20863}
}
EUVIMED